Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic rituximab in EBV-negative adult kidney transplant recipients
2020-000492-21Phase 3Active
- Sponsor
- Strasbourg University Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in Epstein-Barr virus infection, Post-Transplant Lymphoproliferative Disorder (PTLD) and kidney transplant (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Composite primary endpoint at 1 year. Started Apr 2021; status: active.
02
Drugs
rituximab
03
Conditions
Epstein-Barr virus infectionPost-Transplant Lymphoproliferative Disorder (PTLD)kidney transplant
Beyond the preview
Go deeper on 2020-000492-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000492-21.